ESC 365 - Rapid Fire session 8 - Atrial fibrillation and stroke prevention
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program - ScienceDirect
GLORIA AF Registry delivery from ESC Ph D
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry | SpringerLink
American Heart Journal American Heart Journal
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA -AF Registry Phase 2 | Journal of the American College of Cardiology
Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF | PLOS ONE
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry | SpringerLink
GLORIA – AF Registry: delivery from ESC - ppt download
GLORIA AF Real World Evidence Study | boehringerone.com
Pradaxa Shows Low Bleeding, Stroke Rates in GLORIA-AF Registry | DAIC
Results of the 1 st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants MV Huisman, - ppt download
Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF | PLOS ONE
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II - The American Journal of Medicine
Results of the 1 st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants MV Huisman, - ppt download
02862-x.fp.png "POLYPHARMACY IN A GLOBAL COHORT OF PATIENTS TAKING ANTICOAGULANTS FOR ATRIAL FIBRILLATION: THE GLORIA-AF REGISTRY | Journal of the American College of Cardiology")
POLYPHARMACY IN A GLOBAL COHORT OF PATIENTS TAKING ANTICOAGULANTS FOR ATRIAL FIBRILLATION: THE GLORIA-AF REGISTRY | Journal of the American College of Cardiology
Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study - European Journal of Internal Medicine
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA -AF Registry Phase 2
Stroke Risk Factors Despite Anticoagulation in Patients with Atrial Fibrillation - Docwire News Stroke Factors in Atrial Fibrillation
Gloria-AF Registry Phase 2 Baseline Data | Download Scientific Diagram
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II - The American Journal of Medicine
Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry - American Journal of Cardiology
Design of GLORIA-AF. m, months; NOAC non-vitamin K antagonist oral... | Download Scientific Diagram
Final Phase II results from the GLORIA-AF registry summarised by Prof. Greg Lip | Radcliffe Cardiology
Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry
